Sana Biotechnology (SANA), a clinical-stage biotech company specializing in gene and cell therapies, has recently experienced significant moves in its stock performance, attracting investor attention.

We recently compiled a list of the 10 Hottest Smid-Cap Stocks So Far In 2025. In this article, we are going to take a look at where Sana Biotechnology, Inc.

https://www.tipranks.com/news/the-fly/fortress-biotech-announces-first-patient-dosed-in-phase-2-trial-of-triplex BofA lowered the firm’s price target on Sana ...

Samantha Semenkow, an analyst from Citi, maintained the Buy rating on Sana Biotechnology (SANA – Research Report). The associated price target remains the same with $15.00. Discover ...

Sana Biotechnology has a 1 year low of $1.52 and a 1 year high of $12.00. Sana Biotechnology ( NASDAQ:SANA – Get Free Report ) last issued its quarterly earnings results on Friday, November 8th.

Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with type 1 diabetes, sending the company’s share price up by about 200%.